Salestools LogoSalestools
Salestools AI Agents
Solutions
Resources
Company
Pricing
Salestools Logo

Salestools

The #1 AI Agent for Sales teams and Go To Market teams. Sell more, faster, with less effort.

Product

  • AI Sales Agents
  • Intent Data
  • Technology Data
  • Visitor Tracking
  • Co-Pilot
  • Social Selling

Solutions

  • Customer Service
  • E-commerce
  • SaaS
  • Enterprise
  • Small Business

Resources

  • The Report
  • Documentation
  • API Reference
  • Help Center
  • Blog
  • Case Studies
  • Webinars

Company

  • About
  • Careers
  • Press
  • Contact
  • Partners

Our locations

  • New York, HQ
  • Bucharest, AI Research Lab
  • Zug, Switzerland

Β© 2026 Salestools. All rights reserved.

Data Terms & SecurityPrivacy PolicyTerms of ServiceAcceptable Use
All systems operational
Salestools LogoSalestools
Salestools AI Agents
Solutions
Resources
Company
Pricing
Back to Reports
Fundraising

Deeproute

Deeproute Raises $100M in Series C

Shenzhen, ChinaNovember 8, 20242 min read
Employees
300+

Deeproute Raises $100M in Series C


Deeproute has successfully raised $100M in a Series C at a $600M valuation led by Alibaba, NIO Capital.


Company Overview


Deeproute is a Autonomous Vehicles company headquartered in Shenzhen, China, founded in 2019 with 300+ employees.


Autonomous driving technology for robotaxis and logistics


Fundraising Details


  • Amount Raised: $100M
  • Round Type: Series C
  • Valuation: $600M
  • Date: 2024-11-08
  • Investors: Alibaba, NIO Capital

About Deeproute


Autonomous driving technology for robotaxis and logistics The company is positioned in the Autonomous Vehicles sector, serving a growing market with innovative solutions.


Key Information


  • Headquarters: Shenzhen, China
  • Founded: 2019
  • Team Size: 300+
  • Industry: Autonomous Vehicles

What This Means


This funding round demonstrates strong investor confidence in Deeproute's vision and execution. The capital will likely be used to:


  • Scale Operations: Expand the team and operational capacity
  • Product Development: Enhance existing products and develop new features
  • Market Expansion: Enter new markets and strengthen presence in existing ones
  • Technology Investment: Invest in infrastructure and technology capabilities

Industry Context


The Autonomous Vehicles sector continues to attract significant investment as companies innovate to meet evolving market demands. Deeproute's successful fundraising reflects the strong fundamentals and growth potential in this space.


Valuation Milestone


Reaching a $600M valuation marks an important milestone for Deeproute, positioning the company among notable players in the Autonomous Vehicles industry.


Looking Ahead


With this new capital, Deeproute is well-positioned to execute on its growth strategy and continue building innovative solutions in the Autonomous Vehicles space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.


This fundraising news was reported on 2024-11-08. For more information about Deeproute, visit their headquarters at Shenzhen, China.

Company Info

Headquarters
Shenzhen, China
Founded
2019
Team Size
300+

Topics

Fundraising(2912)Series C(300)Autonomous VehiclesDeeproute

Share

Related Reports

Fundraising
Tebra

Tebra Raises $250M Growth Financing | Healthcare Practice Management Platform

Healthcare practice management platform Tebra secures $250 million in growth financing led by Hildred Capital for AI-driven automation.

SalesTools Research
SalesTools Research
Jan 12, 2026
0 min readβ€’$250M
Fundraising
Harmattan AI

Harmattan AI Raises $200M Series B | Defense Tech Unicorn at $1.4B Valuation

French defense tech company Harmattan AI secures $200 million Series B led by Dassault Aviation, reaching unicorn status.

SalesTools Research
SalesTools Research
Jan 11, 2026
0 min readβ€’$200M
Fundraising
AirNexis Therapeutics

AirNexis Therapeutics Raises $200M Series A | Novel COPD Treatment

Biotech AirNexis Therapeutics emerges from stealth with $200 million Series A for dual PDE3/4 inhibitor COPD therapy.

SalesTools Research
SalesTools Research
Jan 11, 2026
0 min readβ€’$200M

Turn your sales ideas into reality today

Start your 14-day Pro trial today. No credit card required.

Start building for free